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Abstract
Objective: CeQur Simplicity™ (CeQur, Marlborough, MA) is a 3-day insulin delivery patch designed to meet mealtime
insulin requirements. A recently reported 48-week, randomized, multicenter, interventional trial compared efficacy, safety
and self-reported outcomes in 278 adults with type 2 diabetes (T2D) on basal insulin therapy who initiated and managed
mealtime insulin therapy with a patch pump versus insulin pen. We assessed changes in key glycemic metrics among a subset
of patients who wore a continuous glucose monitoring (CGM) device.
Methods: Study participants (patch, n = 49; pen, n = 48) wore a CGM device in masked setting during the baseline period
and prior to week 24. Glycemic control was assessed using international consensus guidelines for percentage of Time In
Range (%TIR: >70% at 70-180 mg/dL), Time Below Range (%TBR: <4% at <70 mg/dL; <1% at <54 mg/dL), and Time Above
Range (%TAR: <25% at >180 mg/dL; <5% at >250 mg/dL).
Results: Both the patch and pen groups achieved recommended targets in %TIR (74.1% ± 18.7%, 75.2 ± 16.1%, respectively)
and marked reductions in %TAR >180 mg/dL (21.1% ± 19.9%, 19.7% ± 17.5%, respectively) but with increased %TBR <70 mg/
dL (4.7% ± 5.2%, 5.1 ± 5.8, respectively), all P < .0001. No significant between-group differences in glycemic improvements
or adverse events were observed.
Conclusions: CGM confirmed that the patch or pen can be used to safely initiate and optimize basal-bolus therapy using a
simple insulin adjustment algorithm with SMBG. Preference data suggest that use of the patch vs pen may enhance treatment
adherence.
Keywords
mealtime insulin, patch, CGM, time in range, TIR, type 2 diabetes, T2D, SMBG, algorithm

Introduction
Basal-bolus insulin regimens, utilizing long-acting basal
insulin in combination with rapid-acting insulin analogs, provide a physiological approach to achieve optimal glycemic
control in individuals with type 2 diabetes (T2D) who require
insulin therapy.1,2 Studies have shown that intervention with

basal-bolus therapy in newly diagnosed T2D patients facilitates rapid improvement in glycemic control and may help to
preserve beta-cell function.3,4
Despite the demonstrated benefits of basal-bolus regimens, intensification of insulin therapy is often delayed.5-7 A
recent retrospective claims-based U.S. study found that less
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than one third of basal insulin users achieved target glycated
hemoglobin (HbA1c) at 6 months and that mealtime insulin
was prescribed to only 37.7% of these patients.8 This reflects
hesitance on the part of many clinicians to initiate and intensify insulin therapy due to time constraints, lack of knowledge, potential risks of hypoglycemia, variations in guideline
recommendations, and misconceptions about patient fears.9,10
People with T2D often resist insulin initiation/intensification due to fear of injection pain, fear of hypoglycemia, interference with daily activities, embarrassment, concerns about
weight gain and reduced quality of life, as well as clinician
concerns about treatment adherence.10-15 Even when insulin
therapy is initiated or intensified, adherence to therapy is
often inadequate,11,15,16 leading to suboptimal glycemic control. CeQur Simplicity™ (CeQur, Marlborough, MA), a
3-day insulin delivery patch designed to meet mealtime insulin requirements, may address many of these barriers by simplifying insulin delivery.17
We recently reported findings from a 48-week, randomized, multicenter, multi-national open-label, parallel, 2-arm
interventional trial that compared efficacy, safety and selfreported outcomes in 278 T2D adults on basal insulin therapy
who initiated and managed mealtime insulin therapy with the
patch versus insulin pen (NCT02542631).18 Participants utilized a pattern-control logbook, which included data from selfmonitoring of blood glucose (SMBG) and a simple insulin
adjustment algorithm to adjust basal and bolus insulin weekly
based on fasting and premeal glucose targets. At study end,
both the patch and insulin pen groups showed significant
improvements from baseline in glycated hemoglobin (HbA1c)
change (P < .0001) with no differences in adverse events
between patch and pen. Importantly, participant-reported data
at week 48 significantly favored the patch over the pen.
Although HbA1c remains the key surrogate marker for
the development of long-term diabetes complications, this
measure is limited in its ability to identify the frequency,
magnitude and duration of acute glycemic events.19,20 To
address this limitation, the study included a subset of participants who wore a continuous glucose monitoring (CGM)
system (in masked setting) for 1-2 weeks during the baseline
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period and prior to week 24. Glycemic control in these participants was assessed using recently published international
consensus guidelines for the standardization of key CGM
metrics and clinical targets for percentage of Time In Range
(%TIR: >70% at 70-180 mg/dL), Time Below Range
(%TBR: <4% at <70 mg/dL; <1% at <54 mg/dL) and Time
Above Range (%TAR: <25% at >180 mg/dL; <5% at
>250 mg/dL). In this report, we present findings from our
analyses of changes in these metrics within the subset of participants who wore the CGM device during the study.

Methods
Design and Participants
Details of the full cohort study design, inclusion/exclusion
criteria and interventions have been presented elsewhere
(NCT02542631; EudraCT 2015-003761-28).18 In this predefined analysis, a goal of 50 participants in each treatment
arm at a subset of sites who met inclusion/exclusion criteria
for the full cohort study were recruited for this subset analysis if they were willing to wear a CGM device and abstain
from acetaminophen and paracetamol medications for at
least 4 hours prior to CGM and during CGM.

Study Devices
The patch is a small, wearable device (65 × 35 × 8 mm) that
can be worn on the abdomen for up to 3 days.21 The patch
holds up to 200 units of mealtime insulin and delivers a
2-unit dose via a subcutaneous cannula with each simultaneous click of the 2 buttons on either side of the device. The
patch can be worn under clothing and the 2 buttons can be
accessed either directly or through clothing. In the United
States, the patch is approved for use with rapid-acting insulins lispro (Humalog®; Eli Lilly and Co., Indianapolis, IN)
and aspart (NovoLog®/NovoRapid®; Novo Nordisk, Inc.,
Plainsboro, NJ). Insulin aspart (Novo Nordisk, Inc.,
Plainsboro, NJ) was used in the patch during the study. The
comparator device was a NovoLog/NovoRapid FlexPen®
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(insulin aspart) (Novo Nordisk Pharmaceuticals, Inc.,
Princeton, NJ). All participants were provided with Verio IQ
blood glucose meters and test strips (LifeScan, Inc., Wayne,
PA). Participants in the subgroup analysis were provided
Dexcom G4 CGM system (Dexcom, Inc., San Diego, CA)
set in the “masked” mode.

Procedures
Following a 4-week screening and baseline period, all participants were randomized (1:1 to patch or pen) and followed for
44 weeks to evaluate glycemic control, safety, and treatment
experience. Investigators instructed participants to continue
taking their basal insulin either before their evening meal or at
bedtime and use their insulin delivery device (either Patch or
Pen, as randomized) for mealtime insulin administration.
Insulin dosages were initially determined by dividing the
total daily insulin dose between basal and mealtime insulin.
Half the total daily insulin dose was given as basal insulin
and half as mealtime insulin (split evenly between usual
daily meals). In subjects with HbA1c <9.0% at screening,
the daily basal insulin dose was reduced by 10% before splitting into basal and mealtime insulins to decrease the potential for hypoglycemia. Participants were taught how to adjust
their basal and mealtime insulin doses weekly, using a pattern-based logbook combining SMBG values with a simple
insulin adjustment algorithm.22,23
Participants in the CGM subset analysis wore their CGM
devices in masked mode for one week between week −2 to 0
and week 22 to 24. CGM was repeated for a second week
during those periods only if data collection from the first
week was inadequate (eg, <70% data utilization).CGM participants were asked to record 3-day, 7-point glucose values,
insulin doses, hypoglycemic events and other adverse events
in a diary. Throughout the study, participants were asked to
perform SMBG every day before morning, midday, and evening meals, at bedtime, and when hypoglycemia was suspected based on symptoms.
At Week 44, participants crossed over to the other treatment arm for 4 weeks. An investigator-developed survey was
administered to assess participants preference for patch versus pen at 48 weeks.
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and Week 22 to Week 24 periods and who had HbA1c values
at baseline and Week 24. Baseline CGM calculations were
derived from the measurements obtained during Week −2 to
Week 0. Endpoint CGM calculations were derived from the
measurements obtained during Week 22 to Week 24. The
percentage of time when participants had plasma glucose
measurements <54 mg/dL, <70 mg/dL, 70-180 mg/dL,
>180 mg/dL), and >250 mg/dL, were calculated. Unless
otherwise noted, all tests of device effects were conducted at
a two-sided alpha of 0.05, and two-sided confidence intervals (CIs) at 95%. For each item in the patient preference
survey (5-points Likert scale), a favorable response was considered a response of 4 or 5.

Results
Participants
Ninety-seven participants (patch, n = 49; pen, n = 48) had sufficient/adequate CGM sensor data at baseline and week 24.
Baseline characteristics of the patch group were:
57.4 ± 1.5 years, 46.9% female, 14.5 ± 0.9 years diabetes duration, 81.6% white, 8.54% ± 0.90% HbA1c, 162 ± 5.4 mg/dL
fasting glucose, 39.8 ± 2.5 U/day total daily insulin dose and
90.6 ± 2.5 kg body weight. Baseline characteristics of the pen
group were: 60.2 ± 1.1 years, 31.3% female, 15.5 ± 1.1 years
diabetes duration, 95.8% white, 8.75 ± 1.03% HbA1c,
167 ± 2.6 mg/dL fasting glucose, 46.0 ± 3.0 U/day total daily
insulin dose and 97.8 ± 2.3 kg body weight. All participants
were naïve to mealtime insulin therapy.

Outcomes

Outcomes were changes from baseline in the overall mean
glucose and percentage of CGM readings within target range
(70-180 mg/dL), below target ranges (Level 1, <70 mg/dL;
Level 2, <54 mg/dL) and above target range (Level 1,
>180 mg/dL; Level 2, >250 mg/dL) at 24 weeks

CGM metrics showed that both study groups achieved statistically and clinically significant increases in percentage of
time in range and marked reductions in time spent above target range but with increased time spent below target range.
(Table 1)
Reductions in glycemic variability as measured by SD
were significant in both study groups. Significant improvements in HbA1c were observed in both groups at week 24
compared with baseline values. No between-group differences
in CGM metrics or HbA1c improvements were observed.
Ambulatory Glucose Profile (AGP)24,25 plotting showed notable flattening of glycemic profiles in both groups, particularly
during the period from bedtime to morning. (Figure 1)
The majority of participants who wore the patch for
44 weeks reported a preference for using the device for mealtime insulin therapy vs insulin pen. (Table 1) Less constraint
and greater freedom in diabetes self-management were considered important advantages by participants in both groups.

Statistical Analyses

Discussion

The CGM analysis set included all participants who had
CGM measurements obtained during the Week −2 to Week 0

In this cohort of individuals with T2D who were naïve to
basal-bolus insulin therapy, our subset analysis of CGM data

Measures
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Table 1. Change in HbA1c, Average Glucose, Time in Ranges and Overall Glycemic Variability (SD) from baseline as measured by
CGM.
Patch (n = 49)
Metric
Glycemic assessments
70-180 mg/dL, % time
<70 mg/dL, % time
<54 mg/dL, % time
>180 mg/dL, % time
>250 mg/dL, % time
Glycemic Variability (SD), mg/dL
Central lab HbA1c ± SD, %
Average glucose ± SD, mg/dL

Baseline
48.4 ± 25.2
1.2 ± 2.4
0.2 ± 0.7
50.4 ± 26.1
18.3 ± 18.3
52.2
8.54 ± 0.90
189 ± 41.4

Pen (n = 48)

Week 24

P value

Baseline

Week 24

P value

74.1 ± 18.7
4.7 ± 5.2
1.1 ± 2.0
21.1 ± 19.9
5.6 ± 9.7
46.8
6.82 ± 0.95
142 ± 30.6

<.0001
<.0001
<.0001
<.0001
<.0001
<.0017
<.001
<.0001

42.4 ± 23.8
0.9 ± 3.2
0.2 ± 1.2
56.7 ± 24.8
23.4 ± 21.8
54.0
8.75 ± 1.03
199.8 ± 41.4

75.2 ± 16.1
5.1 ± 5.8
1.2 ± 2.0
19.7 ± 17.5
4.6 ± 8.3
45.0
6.70 ± 0.79
140.4 ± 28.8

<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.001
<.0001

Patch (n = 49)

Insulin dose
Mean total Daily dose U/day, ± SE
Mean total insulin dose, U/kg, ± SE
Basal:bolus ratio, %

39.8 ± 2.5
0.43 ± 0.02
52:48

Participant preference (patch vs pen)

Percentage who used patch
for 44 weeks, (n = 45)

95% CI

P-value

77.8%

62.9, 88.8

<.0001

77.8%

62.9, 88.8

<.0001

88.6%
84.4%
82.2%
80.0%

75.4, 96.2
70.5, 93.5
67.9, 92.0
65.4, 90.4

<.0001
<.0001
<.0001
<.0001

77.8%

62.9, 88.8

<.0001

More satisfied using the patch vs the pen for
mealtime insulin therapy
Prefer using the patch vs the pen for mealtime
insulin therapy
Had to carry fewer diabetes supplies with me
Feel less constrained with my diabetes management
Feel more freedom with my diabetes management
Would recommend the patch vs the pen to other
patients who are on mealtime insulin therapy
Want to switch from the pen to the patch

112.4 ± 9.8
1.15 ± 0.09
44:56

Pen (n = 48)
<.0001
<.0001
<.0001

46.0 ± 3.0
0.47 ± 0.03
52:48

131.3 ± 8.1
1.30 ± 0.09
43:57

<.0001
<.0001
<.0001

All CGM glucose categories are shown as % time in range ± SD, unless stated otherwise. Difference between patch and pen at baseline or week 24 was
nonsignificant for all metrics.
CGM, continuous glucose monitoring; HbA1c, glycated hemoglobin; SE, standard error, SD, standard deviation.

Figure 1. Ambulatory glucose profiles (AGP) at baseline and week 24 for patch and pen groups.
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demonstrated that use of a simple insulin adjustment algorithm guided by SMBG improves glycemic control using
either the patch or pen. Importantly, participants in both
study groups achieved the recommended targets for percentage of TIR (>70% at 70-180 mg/dL) and TAR (<25% at
>180 mg/dL) with only slight deviations from time >250 mg/
dL (<5%), time <70 mg/dL (<4%) and time <54 mg/dL
(<1%).19
Many clinicians using a basal only insulin regimen to
treat hyperglycemia, continually increase the basal insulin
dose in an attempt to optimize the fasting glucose. This minimally improves postprandial glucose excursions, leading to
more glycemic variability and potential risk for hypoglycemia.26 As evidenced by the flattened CGM profile over
24 hours, we were able to increase time in range and decrease
glycemic variability through adding prandial insulin to the
regimen and then steadily increasing the prandial dose as
needed, often while decreasing the basal insulin dose.
Although no significant between-group differences in
glycemic measures were observed, participant preference
outcomes favored the patch. Overall, participants expressed
a higher preference for the patch compared with the pen
for administering mealtime insulin. These findings are
similar to those reported by patch users in the full study
cohort, who expressed significantly higher rates of agreement (vs pen users) that they were able to “dose without
attracting attention” (93.8% vs 68.8%, P < 0.0001), “felt
comfortable using it socially” (89.3% vs 71.0%, P < .001)
and “mealtime dosing was painless” (90.2% vs 70.4%,
<.001). As reported by Peyrot et al., social embarrassment
and injection pain are significant contributors to insulin
injection omission, particularly among individuals with
T2D treated with MDI therapy.11 Thus, our findings suggest that patch users may be more inclined to bolus for
meals as prescribed.
Moreover, our findings confirm that the patch provides a
simple and effective alternative to other delivery methods for
safely initiating and optimizing basal-bolus therapy using an
SMBG-driven simple insulin algorithm without CGM.
Although large trials have demonstrated the benefits of CGM
in insulin-treated T2D,27,28 use of this technology may not be
preferable or financially feasible for many individuals.
Key strengths of our analysis were the randomized design
with a comparator arm and a formal protocol for insulin
adjustment/titration. One notable limitation was the potential
for enhanced treatment adherence in both groups due to the
study effect.
As demonstrated by CGM data, our study showed that it
is possible to safely initiate and optimize basal-bolus therapy
using a simple insulin adjustment algorithm with SMBGguided insulin dosing, resulting in increased time in target
and minimal hypoglycemia while achieving a flat 24-hour
glucose profile using either the patch or pen. Our study
showed that CeQur Simplicity offers a safe, preferred alternative to other delivery methods, such as pen.

5

Conclusions
Use of CGM complemented HbA1c outcome measures in
assessing changes in glycemic control, providing further
understanding of glycemic control for patients with T2D initiating basal-bolus therapy. Similar studies using CGM in
combination with our simplified insulin dosing algorithm
would expand our understanding of the clinical utility of this
treatment approach.
Abbreviations
AGP, ambulatory glucose profile; CGM, continuous glucose monitoring; %TAR, percentage of time above range; %TBR, percentage
of time below range; %TIR, percentage of time in range; T2D, .type
2 diabetes.
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